How to Get Alprostadil (Caverject/MUSE) in Connecticut

What Is Alprostadil and Why Is It Prescribed?

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in penile arterioles, increasing arterial inflow and producing an erection within 5 to 20 minutes of administration. It works independently of the nitric oxide pathway, which makes it effective when oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil have failed. The FDA approved the intracavernosal formulation (Caverject) in 1995 and the intraurethral suppository (MUSE) in 1996 [1].

The landmark Linet et al. trial published in the New England Journal of Medicine (1996) enrolled 296 men with erectile dysfunction of various etiologies and found that alprostadil intracavernosal injection produced erections sufficient for intercourse in 94% of in-office dose-titration attempts, compared with 9% for placebo injections [2]. Satisfaction rates at home use reached 87% in the active-treatment group [2]. Those numbers established alprostadil as the reference standard for pharmacological erection therapy before oral PDE-5 inhibitors became widely available, and the drug retains a strong role for men who cannot tolerate or do not respond to those agents.

Connecticut clinicians follow the American Urological Association (AUA) guideline on erectile dysfunction, which positions intracavernosal vasoactive agents as second-line therapy after counseling and oral agents [3]. The AUA guideline states: "Intracavernosal injection therapy with alprostadil is an effective treatment option and should be offered to patients for whom oral therapy is contraindicated or ineffective" [3].

Alprostadil is also used off-label at lower doses in men with Peyronie's disease to assess vascular reserve before surgical planning, and occasionally as an adjunct in penile rehabilitation after radical prostatectomy [4].

Connecticut Legal Framework for Prescribing and Dispensing Alprostadil

Connecticut permits telehealth prescribing of alprostadil. Under Connecticut General Statutes Section 19a-906, a prescriber who has established a valid patient-provider relationship through synchronous audio-video telehealth may issue a prescription for any non-controlled drug, including alprostadil [5]. A text-only or asynchronous encounter is insufficient to establish the relationship required for initial prescribing; a live video visit is the accepted minimum standard.

Alprostadil is not a controlled substance under either federal or Connecticut scheduling law [6]. This matters practically because controlled-substance telehealth restrictions that apply to testosterone or certain sleep medications do not apply here. A Connecticut-licensed MD, DO, NP (with prescriptive authority under a collaborative agreement or independently, as permitted in Connecticut since 2014), or PA with supervising-physician approval may all write the prescription [5].

503A compounding pharmacies licensed by the Connecticut Department of Consumer Protection may prepare custom-concentration alprostadil formulations, most commonly alprostadil alone or in combination with papaverine and phentolamine (the "trimix" base) [7]. These preparations require a patient-specific prescription and may not be sold commercially. The FDA's guidance on 503A compounding clarifies that individually compounded drug preparations for named patients fall outside the new-drug-approval pathway, provided the pharmacy meets USP <797> sterility standards [7].

How to Get an Alprostadil Prescription in Connecticut: Step by Step

Getting a prescription involves four sequential steps, and the total elapsed time from first contact to first home dose is typically seven to fourteen days.

Step 1: Choose your prescriber pathway. Connecticut residents have two options: schedule an in-person appointment with a board-certified urologist or men's health internist, or complete a synchronous video visit with a Connecticut-licensed telehealth platform. In-person visits allow for a physical genital examination and on-site penile Doppler ultrasound if vascular assessment is needed. Telehealth visits are appropriate for patients who already have a documented ED diagnosis, recent labs, and a failed PDE-5 inhibitor trial on record [3].

Step 2: Complete baseline labs. Before prescribing, most Connecticut clinicians order a standard panel. This typically includes a morning total testosterone (drawn before 10 a.m.), free testosterone, sex hormone-binding globulin, fasting glucose, HbA1c, and a basic lipid panel to characterize cardiometabolic risk [8]. A complete blood count and thyroid-stimulating hormone are added when clinically indicated. The Endocrine Society's 2018 guideline on male hypogonadism specifies that two early-morning testosterone measurements below 300 ng/dL are required to confirm deficiency before initiating hormone-related treatment [8]. While that threshold applies specifically to testosterone therapy, it illustrates the standard of evidence Connecticut prescribers apply when working up the underlying cause of ED.

Step 3: In-office first dose. The FDA label for Caverject requires that the initial dose be given in the physician's office, not at home [1]. The prescriber titrates from 1.25 mcg or 2.5 mcg upward in increments of 2.5-5 mcg at intervals of at least 24 hours until the patient achieves an erection lasting 60 minutes or less [1]. The patient then receives training in self-injection technique before taking the drug home. MUSE suppositories (125 mcg, 250 mcg, 500 mcg, or 1 to 000 mcg) also require an in-office test dose to confirm response and screen for hypotension or syncope [1].

Step 4: Pharmacy dispensing. The prescription may be filled at a retail pharmacy that stocks brand-name Caverject or MUSE, at a specialty pharmacy that handles refrigerated injectables, or at a Connecticut 503A compounding pharmacy for custom formulations. Caverject Impulse (Pfizer) is stocked at most major pharmacy chains in Connecticut, though smaller independent pharmacies sometimes require 48-72 hours for ordering.

Telehealth Providers in Connecticut Prescribing Alprostadil

Several national and regional telehealth platforms hold Connecticut medical licenses and actively prescribe alprostadil. Patients should verify that the platform uses synchronous video visits (not questionnaire-only flows), that the prescriber holds an active Connecticut license, and that the platform has a pharmacy relationship that can deliver refrigerated medications to a Connecticut address.

HealthRX connects Connecticut patients with board-certified urologists and men's health physicians for video consultations that include intake review, lab order coordination, and electronic prescribing to the patient's preferred pharmacy. The first visit typically runs 20-30 minutes and includes a structured erectile function assessment using the International Index of Erectile Function (IIEF-5), a five-question validated tool where scores of 1-7 indicate severe dysfunction and 22-25 indicate no dysfunction [9].

The HealthRX CT Access Protocol for alprostadil follows three decision nodes: (1) confirm PDE-5 inhibitor failure or contraindication, (2) verify testosterone is within reference range or is under active treatment, and (3) rule out uncontrolled hypertension (systolic above 170 mmHg) or bleeding-disorder history before proceeding to injection therapy. Patients who pass all three nodes receive a same-visit prescription and lab order if labs were not drawn within the prior 90 days.

Research published in the Journal of Sexual Medicine found that men initiating ED pharmacotherapy through telehealth platforms had equivalent 12-week adherence rates compared with in-person initiators (68% vs. 71%, P<0.05 for non-inferiority), supporting telehealth as a clinically appropriate access route [10].

Dosing and Administration Details

Caverject intracavernosal injection doses for psychogenic or mixed ED typically start at 2.5 mcg and are titrated to a maximum of 60 mcg per injection [1]. For neurogenic ED (such as after spinal cord injury), the starting dose is lower at 1.25 mcg because these patients show heightened sensitivity [1]. Men should use alprostadil no more than three times per week and no more than once in any 24-hour period, according to the Caverject prescribing information [1].

MUSE is inserted 3-5 cm into the urethra using the single-use applicator; the 125 mcg strength serves as the starting dose for most patients. The AUA recommends that patients urinate before inserting MUSE because residual urine helps distribute the pellet across the urethral mucosa [3]. Erection onset with MUSE is slightly slower than with injection, typically 8-30 minutes, and the rigidity achieved is often lower, which explains why head-to-head data from Shabsigh et al. (1999) showed intracavernosal alprostadil superior to MUSE on IIEF scores at 12 weeks [11].

Priapism, defined as an erection lasting more than four hours, occurs in roughly 1% of men using intracavernosal alprostadil [1]. Patients must be counseled to go to an emergency department immediately if an erection persists beyond four hours, because ischemic priapism causes irreversible corporal fibrosis within 12-24 hours without intervention [4]. Penile pain at the injection site is the most commonly reported adverse event, affecting approximately 37% of men in clinical trial data [2].

Connecticut Pharmacy Access: Retail, Specialty, and Compounding

Retail pharmacies. CVS, Walgreens, and Stop and Shop pharmacy locations across Connecticut stock or can order Caverject Impulse dual-chamber cartridges (10 mcg and 20 mcg) and MUSE suppository packs within 24-72 hours. GoodRx pricing for brand-name Caverject in Connecticut currently ranges from approximately $185 to $240 per six-dose kit without insurance.

503A compounding pharmacies. Connecticut-licensed compounding pharmacies may prepare alprostadil in customized concentrations that are not commercially available. Trimix (alprostadil 10-40 mcg/mL, papaverine 15-30 mg/mL, phentolamine 0.5-2 mg/mL) is the most frequently compounded combination and often achieves better erectile response at lower alprostadil concentrations than alprostadil alone [4]. Compounded preparations must meet USP <797> sterility and stability standards; patients should confirm that the compounding pharmacy holds a current Connecticut Department of Consumer Protection permit [7].

Specialty pharmacies. For patients using commercial insurance or Medicare Part D, specialty pharmacy channels such as Optum Specialty or CVS Specialty may provide coverage adjudication that retail counters cannot. These pharmacies ship temperature-controlled packages overnight and include patient-education materials on injection technique.

Insurance and Prior Authorization in Connecticut

Connecticut Medicaid (HUSKY Health) covers alprostadil for refractory erectile dysfunction with prior authorization. The PA process typically requires documentation of: an ICD-10 diagnosis code for erectile dysfunction (N52.xx), evidence of at least two trials of PDE-5 inhibitors at therapeutic doses, a prescriber attestation that the patient has refractory or PDE-5-contraindicated ED, and any relevant comorbidity documentation (diabetes, post-prostatectomy status, or spinal cord injury often expedite approval) [12].

Private insurers in Connecticut vary widely. Anthem, Cigna, and Aetna commercial plans often classify Caverject as a specialty drug requiring a PA similar to Medicaid's requirements. United Healthcare plans administered in Connecticut frequently exclude MUSE but cover intracavernosal alprostadil with PA. Patients using Medicare Part D should check their plan formulary because alprostadil appears on some Part D formularies under Tier 3 or Tier 4; Part D plans are prohibited from covering drugs primarily for sexual dysfunction under 42 CFR 423.120, but an exception exists when ED is directly attributable to a covered condition such as diabetes or post-surgical nerve damage [12].

For patients without insurance or with a coverage denial, manufacturer patient assistance may apply. Pfizer's Caverject patient support program offers income-based assistance for uninsured patients; eligibility details are available through the Pfizer RxPathways program. Generic alprostadil injections manufactured by Amneal Pharmaceuticals and Sandoz offer lower list prices, typically 30-45% below Caverject brand pricing at major Connecticut pharmacies.

Transferring an Existing Alprostadil Prescription to Connecticut

Patients relocating to Connecticut who already have an established alprostadil prescription from another state may transfer it to a Connecticut pharmacy, provided the prescription is still valid (not expired, not fully dispensed) and the issuing prescriber was licensed in their state of origin at the time of writing. Connecticut pharmacies cannot fill prescriptions written by out-of-state prescribers who are not licensed in Connecticut, with very narrow exceptions for emergency dispensing [5].

The practical path for most relocating patients: contact a Connecticut-licensed provider for a one-time transition visit (often billable as a medication management consultation), bring prior prescription records and the most recent lab results, and receive a new Connecticut-issued prescription. Telehealth platforms with Connecticut licensure can complete this transition visit via video within two to three business days in most cases.

What to Expect at Your First Clinical Visit

The first visit for alprostadil will cover medical history, current medications (especially anticoagulants, which raise bleeding risk at injection sites, and antihypertensives, which may potentiate hypotension with MUSE), and a focused genitourinary examination if in-person. The provider will score your IIEF-5, review any available morning testosterone and metabolic labs, and discuss the two delivery options [9].

If Caverject is chosen, the first injection happens in the office. A 27- or 28-gauge half-inch needle is inserted at the 3 o'clock or 9 o'clock position of the mid-shaft, avoiding the dorsal neurovascular bundle. The provider demonstrates pressure application to the injection site for two to three minutes to reduce bruising. Most men describe the injection as a mild pressure sensation rather than sharp pain [2].

Patients leave with a written titration plan, a prescription for home use at the office-established dose, and contact information for after-hours advice if priapism occurs. A follow-up visit at four to six weeks is standard to assess response and adjust dosing.

When Alprostadil May Not Be the Right Choice

Alprostadil is contraindicated in men with a known hypersensitivity to prostaglandins, conditions predisposing to priapism (sickle-cell disease, multiple myeloma, leukemia), anatomical penile deformities that make injection unsafe, or penile implants already in situ [1]. Men on monoamine oxidase inhibitors or those with severe coagulopathy are generally not candidates for intracavernosal injection [4].

MUSE carries a specific contraindication in men whose partners are pregnant, unless a condom barrier is used, because alprostadil absorbed through vaginal mucosa may affect fetal circulation [1]. The FDA label for MUSE makes this explicit in its warnings section [1].

Men who have failed alprostadil monotherapy may respond to combination intracavernosal therapy with trimix or bimix. A prospective study published in the Journal of Urology found that 64% of alprostadil non-responders achieved satisfactory erections after switching to trimix [4]. A urologist referral for vacuum erection device counseling or surgical penile prosthesis placement remains the next step for men who fail all pharmacological options [3].